Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.

Andrea B. Apolo,Thomas Powles,Mauricio Burotto,María T. Bourlon,James J. Hsieh,Umberto Basso,Amishi Yogesh Shah,Cristina Suárez,Camillo Porta,Carlos H. Barrios,Howard Gurney,Elizabeth R. Kessler,Margitta Retz,Saby George,Bernard Escudier,Joshua Zhang,Burcin Simsek,Christian Scheffold,Robert J. Motzer,Toni K. Choueiri

Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.

2021

4553Background: First-line N+C significantly improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) vs S in aRCC patients (pts) in the phase 3 CheckMate ...

Keywords:

Internal medicine
Nivolumab
objective response
Medicine
Oncology
Cabozantinib
Renal cell carcinoma
overall survival
disease characteristics
Sunitinib
Checkmate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations